Global Acute Respiratory Syndrome Treatment Market Report and Forecast 2024-2032

Global Acute Respiratory Syndrome Treatment Market Outlook

The global acute respiratory syndrome treatment market size attained a value of USD 947.08 million in 2023, driven by the mutating variants of COVID-19 and other emerging respiratory syndromes. The market is estimated to grow at a CAGR of 10.1% during the forecast period of 2024-2032. With this growth rate, the market value is estimated to reach a value of USD 2251.50 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Acute Respiratory Syndrome Treatment Market: Disease Insights, Symptoms, and Pathophysiology

The small, elastic air sacs (alveoli) in the lungs experience fluid buildup, which results in acute respiratory distress syndrome (ARDS). Less oxygen enters circulation because of the fluid's ability to prevent the lungs from filling with enough air. The organs are deprived of the oxygen they require to function as a result.

People who are already critically ill or have severe injuries are more likely to develop ARDS. The primary symptom of ARDS, severe shortness of breath, typically appear a few hours to a few days after the injury or illness that caused it. Age and sickness severity both raise the probability of death. Among those who survive ARDS, some make a full recovery while others have lung damage that lasts for a lifetime.

The severity of ARDS's signs and symptoms might vary depending on the condition's origin, its severity, and whether the underlying heart or lung illness is present or not. They consist of severe breathlessness, breathing that is laboured and unusually quick, reduced blood pressure, dizziness, and excessive fatigue

The smallest blood arteries in the lungs leak fluid into the tiniest air sacs where the blood is oxygenated, which is the mechanical cause of ARDS. This fluid is typically kept in the vessels by a protective barrier. However, severe disease or injury can harm the membrane, resulting in fluid leakage and ARDS.

A few causative factors include  the following:

Sepsis: It is a dangerous and widespread bloodstream infection and is the most typical cause of ARDS.

Inhalation: Breathing in dangerous toxins. ARDS may develop as a result of breathing toxic gases, excessive smoke concentrationkis, aspirating vomit, or near-drowning incidents.

Pneumonia: All five lobes of the lungs are typically affected by severe pneumonia.

Injury: Chest, head, or any serious damage. Accidents that cause direct damage to the lungs or the area of the brain that regulates respiration include slips, trips, and falls.

Others like burns, major blood transfusions, and pancreatitis (pancreatic inflammation).

Who is at the Risk of Acute Respiratory Syndrome?

Majority of people who develop ARDS are already ill or injured. While it is unclear who will develop ARDS, several factors, like advanced age, history of tobacco and alcohol consumption, presence of chronic lung disease, or high-risk surgery could lead to higher vulnerability. 

Diagnosis of Acute Respiratory Syndrome

To assist in the diagnosis of ARDS, several diagnostic tests are employed. These tests identify the infection's source, evaluate the state of the lungs, and rule out other illnesses that present with comparable symptoms. Imaging, blood testing, and analysis of sputum (the mixture of saliva and mucus that is coughed up) are procedures that can be used to diagnose acute respiratory distress syndrome.

Epidemiology of Acute Respiratory Syndrome Treatment Market

The percentage of patients with ARDS who are admitted to intensive care units is between 10 and 15 percent . Geographically, ARDS incidence varies and may be greater in the United States and Europe than in other regions. According to the acute respiratory syndrome market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Breakup by Drug Class:

• Vasoconstrictor

• Bronchodilators

• Steroids

• Antibiotics

• Nitric Oxide

• Sedatives and Paralytics

• Surfactant

• Others

Breakup by Route of Administration:

• Oral

• Inhalation

• Parenteral

• Others

Based on the Treatment Channel:

• Public

• Private

Market Breakup by Region:

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Therapeutic Landscape  of the Acute Respiratory Syndrome Treatment Market

No medication has been proven to be successful in preventing or treating ARDS. The goal of treatment is to keep the patient comfortable as the lungs heal. The objective of supportive care is to treat the injury that led to the development of ARDS and get enough oxygen into the blood and distributed to your body to stop damage. 

A few management techniques are as suggested:

Ventilator Support: Extra oxygen is required for all ARDS patients. Typically, oxygen alone is insufficient and excessive oxygen can harm the lungs. A ventilator is a device that facilitates breathing by helping to reopen closed airways. Through a face mask or a tube put into the windpipe, the patient is connected to the ventilator.

Prone Positioning: Patients with ARDS usually lie on their backs in bed. ARDS patients may occasionally be flipped over onto their stomachs to increase blood oxygen levels when oxygen and ventilator therapies are being used at high levels, but blood oxygen levels are still low. Proning is a technique that can temporarily raise blood oxygen levels. It is a challenging task, and some patients are too ill to benefit from this therapy.

Fluid Management: Patients with ARDS are given diuretics to make the patients urinate more frequently in an effort to flush the body of extra fluid and prevent it from accumulating in the lungs. Care must be taken since excessive fluid loss might reduce blood pressure and cause renal issues.

Extracorporeal Membrane Oxygenation (ECMO): In ECMO, blood is removed from the body and pumped across a membrane that adds oxygen and removes carbon dioxide before returning the blood to the body. This therapy carries a high risk and several potential drawbacks. It is not appropriate for all ARDS patients.

Emerging Therapeutic Opportunities  in the Acute Respiratory Syndrome Treatment Market

Due to the diverse aetiology and pathophysiology of ARDS, personalised therapy is intrinsically difficult. But repurposing medications that have been investigated in untargeted/unenriched populations could be just as inventive and promising for ARDS research as novel experimental therapeutics, including for COVID-19 ARDS. Timing, clinical phenotypes, and biologic phenotypes are some potential therapeutic targets. 

Multiple medicines can also be promptly and flexibly investigated with adaptive clinical trial design. It is also possible to individually tailor supportive measures, such as ventilator management and hydration strategy. Novel therapeutics are also in the works, in addition to possible repurposing/targeting of current medications and supportive care techniques.

Suppliers Landscape of the Acute Respiratory Syndrome Treatment Market

The report gives an in-depth analysis of the key players involved in the acute respiratory syndrome treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• AIkido Pharma Inc.

• Aceto Corporation

• Global BioLife Inc Ltd

• Faron Pharmaceuticals

• PhaseBio Pharmaceuticals

• Sage Therapeutics

• Emergent BioSolutions

• Direct Biologics

• Kiniksa Pharmaceuticals, Ltd

• Biomarck Pharmaceuticals, Ltd.

• Athersys, Inc.

Key Highlights of the Report

Acute Respiratory Syndrome Treatment Market Report Snapshots

Acute Respiratory Syndrome Treatment Market Size

Acute Respiratory Syndrome Treatment Companies